nanotrastuzumab / Nanoform - LARVOL DELTA

Preclinical Study Finds Subcutaneous Nanotrastuzumab Comparable to Herceptin HYLECTA in Minipig Model (BioPharm International) - "A preclinical study evaluating Nanoform’s nanoparticle-engineered formulation of trastuzumab demonstrated pharmacokinetic comparability and favorable tolerability relative to Herceptin HYLECTA in a 21-day Göttingen minipig model...According to the company, the data indicate that SC exposure comparable to a hyaluronidase-enabled product may be achievable using a nanoparticle suspension approach alone."

PK/PD data • Preclinical • Solid Tumor

DEVELOPMENT OF NANOFORMED TRASTUZUMAB FOR SUBCUTANEOUS INJECTION TO BE PRESENTED AT DDF SUMMIT IN BERLIN (TradingView) - "Nanoform Finland Plc...announced it had successfully generated nanotrastuzumab, a high concentration nanoformulation of trastuzumab, suitable for subcutaneous injection....On June 3, 2025, Frederique Bordes-Picard, Nanoform’s VP Europe, is to present further data on Nanoform’s nanotrastuzumab development program at the Drug Delivery & Formulation (DDF) Summit in Berlin, Germany....The presentation will show how Nanoform's patented Bio platform overcomes the challenge of delivering high doses through the SubQ route, using a high concentration nanotrastuzumab developed as a non-aqueous suspension as model compound."

Clinical • Breast Cancer • Gastrointestinal Cancer